

No. 340

27 March 2008

MEDICINES AND RELATED SUBSTANCES ACT 1965**REGULATIONS RELATING TO A TRANSPARENT PRICING SYSTEM FOR
MEDICINES AND SCHEDULED SUBSTANCES****INFORMATION TO BE PUBLISHED BY MANUFACTURERS AND
IMPORTERS OF MEDICINES AND SCHEDULED SUBSTANCES BEFORE
TAKING AN INCREASE IN THE SINGLE EXIT PRICE**

The Director-General of Health has determined in accordance with Regulation 21 of the Regulations Relating to A Transparent Pricing System for Medicines and Scheduled Substances published in Government Gazette Number 28214 of 11 November 2005 that the following information in both electronic (Excel format) and document form must be communicated to the Directorate: Pharmaceutical Economic Evaluation within the National Department of Health by a manufacturer or importer of the medicine or scheduled substance in respect of which it intends to take an price increase:

1. NAPPI Code (9-digit);
2. Brand name;
3. Active ingredients;
4. Strength and dosage form
5. pack size;
6. ex-manufacturer price as at 01 January 2008;
7. new increased ex-manufacturer price
8. logistic fee as at 01 January 2008
9. new increased logistic fee
10. Value Added Tax
11. New single exit price after the increase


MR. B. MSELEKU**DIRECTOR-GENERAL: HEALTH****DATE: 2008-03-19**